Drugs / T3011
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06283303 | Apr 2024 → Nov 2025 | metastasis from malignant tumor of colon | China Medical University, China | Unknown | No outcome recorded |
| Phase 1 | NCT06200376 | Sep 2023 → Dec 2024 | — | West China Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT06427291 | Sep 2023 → Dec 2025 | urinary bladder cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1 | NCT06200363 | Sep 2023 → Nov 2024 | colorectal cancer | West China Hospital | Unknown | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06214156 | Jan 2024 → Sep 2026 expected | melanoma | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06214143 | Jan 2024 → Dec 2026 expected | cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05598268 | Mar 2022 → Jun 2024 | liver cancer, lung cancer, lymphoma, pleural mesothelioma | ImmVira Pharma Co. Ltd | Unknown | No outcome recorded |
| Phase 1/2 | NCT04780217 | Aug 2021 → Mar 2025 | colorectal cancer, endometrial cancer, hepatocellular carcinoma, non-small cell lung carcinoma +1 | ImmVira Pharma Co. Ltd | Unknown | No outcome recorded |
| Phase 1/2 | NCT04370587 | Sep 2020 → Sep 2026 expected | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, sarcoma | ImmVira Pharma Co. Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05602792 | Apr 2020 → Jul 2023 | breast cancer, esophageal cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma +2 | ImmVira Pharma Co. Ltd | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06971614 | Jun 2025 → Dec 2028 expected | urinary bladder carcinoma | ImmVira Pharma Co. Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT05756556 | Jun 2024 → Dec 2026 | melanoma | ImmVira Pharma Co. Ltd | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T3011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06200376 ↗ |
| Modality | Other / unclassified | “T3011 Herpes Virus Injection” NCT05598268 ↗ |
| Route | Intravenous | “through IV drip” NCT04780217 ↗ |